Related Experiment Videos
Phosphate therapy in diabetic ketoacidosis
Archives of Internal Medicine
|March 1, 1982
Summary
Phosphate replacement therapy in diabetic ketoacidosis (DKA) is not essential. While it can prevent hypophosphatemia, it does not improve DKA treatment outcomes or patient mortality.
Area of Science:
- Endocrinology
- Metabolic Disorders
- Critical Care Medicine
Background:
- Diabetic ketoacidosis (DKA) is a serious complication of diabetes.
- Hypophosphatemia can occur during DKA treatment.
- Phosphate replacement is a potential therapeutic intervention.
Purpose of the Study:
- To evaluate the efficacy of phosphate replacement in DKA therapy.
- To determine if phosphate supplementation impacts DKA resolution and patient outcomes.
Main Methods:
- 44 patients with DKA were randomized into three groups.
- Groups received no phosphate, a single 15 mmole dose, or multiple 15 mmole doses of sodium phosphate.
- All patients received standard DKA treatment including insulin, fluids, and potassium.
Main Results:
- A single 15 mmole dose of phosphate did not maintain serum phosphate levels.
- 45 mmole of phosphate prevented severe hypophosphatemia and maintained higher phosphate levels.
- Phosphate therapy did not alter DKA duration, insulin requirements, enzyme levels, glucose metabolism, or mortality.
Conclusions:
- Phosphate therapy is not essential for most patients with DKA.
- While effective in preventing hypophosphatemia, it does not improve overall treatment efficacy or clinical outcomes.